Hepion raises $2.06M via warrant inducement, reduces exercise prices and issues new warrants

Hepion Pharmaceuticals, Inc.

Holders of 980,393 Series B warrants will exercise at reduced price of $2.10/share, raising ~$2.06M gross proceeds.
As inducement, Company reduces Series A warrant exercise price to $1.91 (from $4.85) and extends expiration to Feb 2029.
Company issues new Series B-1 and B-2 warrants to purchase up to 735,295 shares each at $1.91.
Engaged A.G.P./Alliance Global Partners as financial advisor; cash fee of 7% of gross proceeds.
Net proceeds to be used for general working capital and corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.